Endocrinology

Top Story

FDA advisory panel recommends approval for Sanofi-Aventis’ iGlarLixi combination drug

May 25, 2016

WASHINGTON — An FDA advisory panel has recommended approval of Sanofi-Aventis’ new drug application 208673 for insulin glargine and lixisenatide injection, to be known as IGlarLixi, for treatment of patients with type 2 diabetes.

The Endocrinologic and Metabolic Drugs Advisory Committee voted 12-2 in favor of recommending approval of iGlarLixi, a titratable fixed-ratio combination of basal insulin glargine 100 U/mL (Lantus) and lixisenatide, a glucagon-like peptide-1 receptor agonist.

Meeting News CoverageVideo

VIDEO: Select patients may benefit from bisphosphonate holidays

May 25, 2016
ORLANDO, Fla. — In this video, AACE President Pauline Camacho, MD, FACE, discusses her approach to osteoporosis management. Rare medication side effects are…
Meeting News Coverage

Transculturalization initiative addresses diverse needs in Latin American patient care

May 25, 2016
ORLANDO, Fla. — New recommendations spearheaded by the American Association of Endocrinologists and the American College of Endocrinology will help bridge the…
Meeting News Coverage

AACE unveils new clinical practice guideline for obesity management

May 25, 2016
ORLANDO, Fla. — A patient-centric approach to obesity management that individualizes treatment and focuses on overall health — not just weight loss —…
Meeting News Coverage

AACE/ACE app offers clinical guidance for management of type 2 diabetes

May 25, 2016
ORLANDO, Fla. —The American Association of Clinical Endocrinologists and the American College of Endocrinology announced the worldwide availability of an in-depth…
More News Headlines »
CME

Diabetic Eye 2015: New Concepts in Screening, Managing, and Referral

This activity is supported by an educational grant from Allergan, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
Video
Meeting News Coverage

VIDEO: EDCs affect development across generations

April 8, 2016
More »
Featured
Highlights from AACE

Highlights from AACE

CME

Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Diabetic eye disease is one of the most common causes of vision loss in the United States. As the rates of diabetes…
More »
Current Issues
View the Current Issues
morganatic-roan